RARE · Ultragenyx Pharmaceutical Inc. · Executive Compensation
$17.38
-0.35 (-1.97%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.81B
Shares
101.92M
Volume · Nov 19
948.26K
Avg daily vol (3M)
4.67M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $11,405,535 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $4,045,072 |
| Eric Crombez | Chief Medical Officer and Executive Vice President | $4,002,173 |
| Howard Horn | Chief Financial Officer, Corporate Strategy and Executive Vice President | $3,750,607 |
| Karah Parschauer | Chief Legal Officer and Corporate Affairs, Executive Vice President | $3,509,313 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $13,717,687 |
| Eric Crombez | Chief Medical Officer and Executive Vice President | $4,298,223 |
| Howard Horn | Chief Financial Officer, Corporate Strategy and Executive Vice President | $4,296,049 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $4,295,813 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $4,129,753 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $13,077,993 |
| Howard Horn | Chief Financial Officer, Corporate Strategy and Executive Vice President | $5,941,040 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $4,068,567 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $4,049,853 |
| Karah Parschauer | Chief Legal Officer & Corporate Affairs and Executive Vice President | $4,036,544 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $12,140,330 |
| Mardi Dier | Former Chief Financial Officer and Executive Vice President | $4,436,756 |
| Camille Bedrosian | Chief Medical Officer and Executive Vice President | $3,755,268 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $3,748,555 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $3,706,511 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $9,522,738 |
| Camille Bedrosian | Chief Medical Officer and Executive Vice President | $3,344,722 |
| Mardi Dier | Former Chief Financial Officer and Executive Vice President | $3,331,874 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $3,317,210 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $3,263,220 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mardi Dier | Former Chief Financial Officer and Executive Vice President | $6,120,642 |
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $5,144,220 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $2,224,299 |
| Camille Bedrosian | Chief Medical Officer and Executive Vice President | $2,214,680 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $2,177,640 |
| Shalini Sharp | Former Chief Financial Officer and Executive Vice President | $793,249 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $6,553,142 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $3,333,238 |
| Shalini Sharp | Former Chief Financial Officer and Executive Vice President | $2,572,184 |
| Camille Bedrosian | Chief Medical Officer and Executive Vice President | $2,485,654 |
| Thomas Kassberg | Chief Business Officer and Executive Vice President | $2,456,501 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $2,273,392 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Camille Bedrosian | M.D. Chief Medical Officer and Executive Vice President | $4,836,128 |
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $4,812,800 |
| Shalini Sharp | Former Chief Financial Officer and Executive Vice President | $2,027,960 |
| Thomas Kassberg | Chief Business Officer and Executive Vice President | $1,692,660 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $1,564,878 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $641,070 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Emil D. Kakkis | M.D., Ph.D. President and Chief Executive Officer | $6,684,899 |
| Shalini Sharp | Chief Financial Officer and Executive Vice President | $2,642,719 |
| Thomas Kassberg | Chief Business Officer and Executive Vice President | $2,331,661 |
| John R. Pinion II | Chief Quality Officer and Executive Vice President, Translational Sciences | $1,919,329 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Daniel G. Welch | Class I Director | Appointed | 2026-05-18 |
| Shehnaaz Suliman, M.D. | Class I Director |
Already on the board
Since at least 2023: re-election or new board role
|
2026-05-18 |
| Emil D. Kakkis, M.D., Ph.D. | Class I Director |
Already on the board
Since at least 2023: re-election or new board role
|
2026-05-18 |
| Amrit Ray, M.D. | Class III director | Appointed | 2025-05-19 |
| Matthew K. Fust | Class III director | Appointed | 2025-05-19 |
| Corsee Sanders, Ph.D. | Class II Director | Appointed | 2024-06-21 |
| Michael Narachi | Class II Director | Appointed | 2024-06-21 |
| Deborah Dunsire, M.D. | Class II Director | Appointed | 2024-06-21 |
| Howard Horn | Chief Financial Officer and Executive Vice President, Corporate Strategy | Appointed | 2023-09-08 |
| Howard Horn | Chief Financial Officer and Executive Vice President, Corporate Strategy | Appointed | 2023-07-12 |
| Daniel G. Welch | Class I Director | Appointed | 2023-06-13 |
| Shehnaaz Suliman, M.D. | Class I Director | Appointed | 2023-06-13 |
| Emil D. Kakkis, M.D., Ph.D. | Class I Director | Appointed | 2023-06-13 |
|
Lars Ekman, M.D., Ph.D.
“Dr. Ekman’s decision to retire from the Board is for personal reasons and is not related to any disagreement with the Company or its management on the Company’s operation, policies, or practices.”
|
Board of Directors | Retired | 2023-03-23 |
| Eric Crombez, M.D. | Executive Vice President, Chief Medical Officer | Appointed | 2023-03-14 |
| Mardi Dier | Executive Vice President and Chief Financial Officer | Resigned | 2022-11-10 |
| Amrit Ray, M.D. | Class III director | Appointed | 2022-04-22 |
Leadership
- Emil D. Kakkis CEO, Board Member
- Emil Kakkis CEO, Board Member
- Howard Horn CFO
- Eric Crombez, M.D. CTO
- Karah Parschauer General Counsel
- Amrit Ray, M.D. Board Member
- Clay B. Siegall Board Member
- Continuing Directors Board Member
- Corazon (Corsee) D. Sanders, Ph.D. Board Member
- Corsee Sanders, Ph.D. Board Member
- Daniel G. Welch Board Member
- Deborah Dunsire Board Member
- Deborah Dunsire, M.D. Board Member
- Emil D. Kakkis, M.D., Ph.D. Board Member
- Lars Ekman Board Member
- Matthew K. Fust Board Member
- Michael Narachi Board Member
- Shehnaaz Suliman Board Member
- Shehnaaz Suliman, M.D. Board Member
- William Aliski Board Member
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
293 filings
265 filers
Visit website
Investor relations